Vanguard Group Inc. Sells 58,726 Shares of Hologic, Inc. (NASDAQ:HOLX)

Vanguard Group Inc. reduced its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 0.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,893,638 shares of the medical equipment provider's stock after selling 58,726 shares during the period. Vanguard Group Inc. owned 11.91% of Hologic worth $1,938,762,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. Cerity Partners LLC grew its stake in Hologic by 50.6% during the third quarter. Cerity Partners LLC now owns 59,884 shares of the medical equipment provider's stock worth $4,878,000 after purchasing an additional 20,132 shares during the period. Centaurus Financial Inc. acquired a new stake in shares of Hologic during the 3rd quarter worth approximately $453,000. Loomis Sayles & Co. L P grew its position in shares of Hologic by 29.3% during the 3rd quarter. Loomis Sayles & Co. L P now owns 808 shares of the medical equipment provider's stock worth $66,000 after buying an additional 183 shares during the period. Private Trust Co. NA lifted its position in shares of Hologic by 19.6% during the 3rd quarter. Private Trust Co. NA now owns 1,166 shares of the medical equipment provider's stock valued at $95,000 after acquiring an additional 191 shares during the period. Finally, Bank of Montreal Can lifted its position in shares of Hologic by 3.9% during the 3rd quarter. Bank of Montreal Can now owns 492,210 shares of the medical equipment provider's stock valued at $39,780,000 after acquiring an additional 18,532 shares during the period. 94.73% of the stock is owned by institutional investors.

Remove Ads

Analyst Ratings Changes

Several brokerages have recently weighed in on HOLX. Jefferies Financial Group began coverage on shares of Hologic in a report on Tuesday, December 10th. They set a "hold" rating and a $85.00 price objective on the stock. William Blair reaffirmed an "outperform" rating on shares of Hologic in a research note on Thursday, February 6th. Stephens reissued an "overweight" rating and issued a $84.00 price objective on shares of Hologic in a research note on Thursday, February 6th. Leerink Partnrs downgraded Hologic from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 6th. Finally, Leerink Partners cut Hologic from an "outperform" rating to a "market perform" rating and cut their target price for the stock from $80.00 to $75.00 in a report on Thursday, February 6th. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Hologic presently has an average rating of "Hold" and an average target price of $84.62.

Hologic Stock Up 0.7 %

Hologic stock traded up $0.45 during midday trading on Monday, hitting $61.77. 2,036,389 shares of the stock were exchanged, compared to its average volume of 1,810,593. Hologic, Inc. has a 52-week low of $60.34 and a 52-week high of $84.67. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The business's 50-day moving average price is $65.08 and its 200-day moving average price is $73.11. The stock has a market capitalization of $13.86 billion, a price-to-earnings ratio of 19.49, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, research analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.